|
시장보고서
상품코드
2126537
결핵 치료제 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)Tuberculosis Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요 :
- 결핵 치료제 시장은 2025년에 41억 5,000만 달러로 추정되며, 2034년까지 68억 달러에 달할 것으로 전망됩니다. 이러한 성장의 배경에는 전 세계에서 여전히 높은 수준을 유지하고 있는 결핵 유병률, 단기간의 전구강 내성 결핵 치료 요법의 도입 가속화, 그리고 결핵 유병률이 높은 국가들에서의 차세대 항결핵제 접근성 확대가 있습니다.
- 전 세계 결핵 치료제 시장은 2026-2034년까지의 예측 기간 중 연평균 성장률(CAGR) 5.7%로 성장하고 있습니다.
- 약제 유형별로는 2025년에 1차 선택 항결핵제 부문이 54%의 점유율을 차지하며 결핵 치료제 시장을 주도했습니다.
- 질환 유형별로는 2025년에 활동성 결핵 부문이 69%의 점유율을 차지하며 결핵 치료제 시장을 독점했습니다.
- 제형별로는 2025년에 정제 부문이 61%의 점유율을 차지하며 결핵 치료제 시장을 주도했습니다.
- 환자 유형별로는 2025년에 성인 부문이 72%의 점유율을 차지하며 결핵 치료제 시장을 주도했습니다.
- 유통 채널별로는 2025년에 병원 약국 부문이 결핵 치료제 시장에서 44%의 점유율을 차지하며 시장을 주도했습니다.
- 아시아태평양은 2025년 49%의 점유율로 전 세계 결핵 치료제 시장의 매출을 주도하며, 전 세계에서 가장 높은 지역별 시장 점유율을 차지했습니다. 이는 전 세계 결핵 부담이 해당 지역에 집중되어 있음을 반영합니다.
결핵 치료제에는 결핵균(Mycobacterium tuberculosis)에 의해 유발되는 활동성 결핵, 잠복 결핵 감염, 다제내성 결핵(MDR-TB) 및 광범위 내성 결핵(XDR-TB)의 예방, 치료, 관리에 사용되는 항결핵제가 포함됩니다. 약물 감수성 활동성 결핵의 표준 치료는 1차 선택 약물인 이소니아지드, 리팜피신,피라지나미드, 에탐부톨을 핵심으로 하며, 직접 관찰 하 치료 프로그램에서 복약 순응도를 높이고 복용 부담을 줄이기 위해 대부분의 경우 고정 용량 복합제로 투여됩니다. 약물 내성 결핵에는 베다킬린, 프레토마니드, 리네졸리드,델라마니드, 플루오로퀴놀론계 약물 등의 2차 치료제가 필요하며, 이들은 기존의 18-20개월에 걸친 주사제를 포함한 치료 요법 대신, BPaL이나 BPaLM과 같이 더 짧은 기간 중 전적으로 경구 투여하는 요법으로 점점 더 널리 채택되고 있습니다. 시장은 약물 유형별(1차 선택약, 2차 선택약/약제 내성 결핵 치료제, 고정 용량 복합 요법), 질환 유형별(활동성 결핵, 잠복성 결핵, 다제내성 결핵(MDR-TB), 광범위 내성 결핵(XDR-TB)),제형별(정제, 캡슐, 주사제), 환자군별(성인, 소아, 고령자), 유통 경로별(병원 약국, 소매 약국, 온라인 약국, 국가 결핵 대책 프로그램 진료소 등 기타 경로)로 분류됩니다. 전 세계 결핵 부담의 규모, 단기 약물 내성 결핵 치료 요법의 급속한 보급, 자발적 라이선싱을 통한 제네릭 의약품 접근성 확대, 그리고 정부 및 국제 보건 파트너들의 지속적인 투자에 힘입어, 결핵 치료제는 전 세계에서 감염병 대응을 위한 공중보건 인프라의 초석으로 자리 잡고 있습니다.
결핵 치료제 시장의 주요 성장 동인
- 전 세계에서 여전히 높은 결핵 부담이 수요를 지원하고 있으며, WHO의 '2025년 세계 결핵 보고서'에 따르면 2024년에는 1,070만 명이 결핵에 걸리고 120만 명 이상이 사망한 것으로 추정됩니다.
- 다제내성 결핵(MDR-TB) 및 내성 회복 결핵(RR-TB)에 대한,투여 기간이 단축되고 모두 경구 투여가 가능한 BPaLM/BPaL 요법이 각국 및 전 세계에서 빠르게 채택되고 있으며, 여기에는 인도가 2024년 9월 ‘국가 결핵 퇴치 프로그램’의 일환으로 BPaLM을 승인한 것도 포함됩니다. 이에 따라 베다킬린, 프레토마니드, 리네졸리드에 대한 수요가 확대되고 있습니다.
- 결핵 부담이 큰 저·중소득국의 제약 기업을 대상으로 베다킬린 및 프레토마니드의 제네릭 의약품 제조를 가능하게 한 자발적 라이선싱 계약을 통해 접근성이 확대되고, 해당 제네릭 의약품 시장도 성장하고 있습니다.
- 정부 주도의 국가 결핵 퇴치 프로그램과 글로벌 펀드(Global Fund) 및 글로벌 드럭 시설(GDF)과의 공급 계약을 포함한 전 세계 보건 파트너들의 조달을 통해 1차 선택 약물 및 고정 용량 복합제(FDC) 요법에 대한 공공 부문의 대량 수요가 지속적으로 지원되고 있습니다.
- 소아에게 적합한 분산형 고정 용량 복합제 및 리파펜틴을 주성분으로 하는 3HP 요법을 포함한 잠복 결핵 예방 요법에 대한 투자 확대로 인해 치료 대상 환자층이 확대되고 있습니다.
- TB 얼라이언스 및 업계 파트너들에 의한 신규 항결핵제 후보 및 차세대 치료법의 개발 파이프라인이 후기 단계에서 활발히 진행되고 있으며, 예측 기간 중 혁신 주도형 성장이 지속될 것으로 전망됩니다.
- 다제내성 결핵 및 광범위 내성 결핵의 발생률이 지속되고 일부 지역에서는 증가 추세를 보이고 있으며, 더 비싸고 전문적인 2차 치료에 대한 의존도가 높아지고 있습니다.
결핵 치료제 시장의 성장에 기여하는 요인
시장 촉진요인
전 세계에서 높고 지속적인 결핵의 질병 부담
결핵 치료제 시장의 가장 큰 촉진요인은 이 질병의 부담이 매우 크다는 점입니다. WHO의 ‘2025년 세계 결핵 보고서’에 따르면 2024년에는 1,070만 명이 결핵에 걸리고 120만 명 이상이 사망한 것으로 추정되며, 결핵은 여전히 단일 병원체에 의한 세계 사망 원인 중 상위권을 차지하고 있습니다. 증례의 약 87%는 인도, 인도네시아, 필리핀, 중국, 파키스탄, 나이지리아, 콩고 민주 공화국, 방글라데시를 필두로 하는 30개 결핵 고부담 국가에 집중되어 있습니다. 2015-2024년에 전 세계 결핵 유병률은 12%, 결핵으로 인한 사망자 수는 29% 감소했으나, 이 모두 ‘결핵 퇴치 전략(End TB Strategy)’이 제시한 2025년 목표에는 여전히 크게 미치지 못하며,치료가 필요한 환자의 절대 수는 여전히 많은 상태입니다. 이러한 지속적인 환자 수의 다수는 예측 기간 중 1차 치료제, 고정용량복합제(FDC), 그리고 특수 약물 내성 치료제에 대한 견고하고 대량의 수요를 지원하고 있습니다.
치료 기간 단축 및 전구강형 약물 내성 결핵 치료 요법의 급속한 보급
오랫동안 주사제를 포함한 다제내성결핵(MDR-TB) 치료 요법에서 단기적이고 전경구 병용 요법으로의 전환이 시장내 수요 구조를 변화시키고 있습니다. WHO가 권장하는 6개월간의 BPaLM 요법(베다킬린, 프레토마니드, 리네졸리드, 목시플록사신)은 18-20개월까지 소요될 수 있는 기존 요법을 대체하여 치료 완료율과 환자의 내약성을 향상시키고 있습니다. 인도 보건가족복지부는 2024년 9월 ‘국가 결핵 퇴치 프로그램’의 일환으로 BPaLM을 승인하여, 이 단기 치료법을 수만 명의 약제 내성 결핵 환자에게 확대 적용했습니다. 또한 결핵 부담이 큰 다른 국가들도 유사한 도입 절차를 진행하고 있습니다. BPaLM은 수요를 소수의 2차 치료제에 집중시키기 때문에 베다킬린, 프레토마니드, 리네졸리드의 제조사 및 해당 제네릭 의약품 제조사들에게 대상 시장을 직접적으로 확대하고 있습니다.
시장 억제요인
수요의 펀더멘털은 양호함에도 불구하고 결핵 치료제 시장은 중대한 제약에 직면해 있습니다. 전 세계 결핵 대책 자금은 여전히 심각한 부족 상태에 있으며, WHO 보고서에 따르면 자금은 2027년 목표액의 불과 약 25% 수준에 그치고 있으며, 기부자들의 자금 삭감이 지속될 경우 2025-2035년 사이에 결핵으로 인한 사망자가 최대 200만 명,신규 환자 수가 1,000만 명 증가할 가능성이 있다고 경고하고 있습니다. 이는 프로그램 차원의 의약품 조달 및 치료의 지속성을 직접적으로 위협하는 요소입니다. 진단 측면의 과제가 이 위험을 더욱 심각하게 만들고 있습니다. 2024년 신속 분자 검사의 보급률은 고작 54%에 그치고 있으며, 상당수의 사례가 진단되지 않거나 치료받지 못한 채, 혹은 내성 여부가 확인되지 않은 상태에서 경험적 치료를 받고 있는 실정입니다. 제네릭 의약품의 가격 하락은 접근성 향상에는 기여하지만, 자발적 라이선싱 확대에 따른 경쟁 심화 속에서 1차 선택약 및 점점 더 많은 2차 선택약 제조사의 이익률을 압박하고 있습니다. 리네졸리드 및 기타 2차 치료제의 부작용 프로파일을 고려할 때, 투여 기간이 단축된 치료법이라 하더라도 복약 순응도는 여전히 과제로 남아 있습니다. 또한 낙인, 빈곤, 취약한 의료 인프라가 감염 부담이 가장 큰 지역에서 치료 접근성 및 치료 완료율을 계속해서 제한하고 있습니다. 진정으로 새로운 작용 기전을 가진 후기 개발 단계의 파이프라인이 비교적 부족한 점, 소수의 2차 치료제 분자에 대한 의존, 그리고 저소득 지역의 진단·치료 인프라 불균형이 질병 부담의 근본적인 요인이며,치료법의 혁신, 그리고 제네릭 의약품에 대한 접근성이 여전히 견고하게 유지되고 있음에도 불구하고 성장 속도를 더욱 둔화시키고 있습니다.
자주 묻는 질문
목차
제1장 결핵 치료제 시장 : 서론
제2장 결핵 치료제 시장 : 개요
제3장 결핵 치료제 시장 : 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제의 동향
제5장 규제 분석
제6장 Porter's Five Forces 분석
제7장 결핵 치료제 시장 : 평가
제8장 결핵 치료제 시장 : 경쟁 구도
제9장 결핵 치료제 시장 : 스타트업 자금조달 및 투자 동향
제10장 결핵 치료제 시장 : 기업 개요 및 제품 개요
제11장 KOL의 견해
제12장 프로젝트 어프로치
제13장 DelveInsight 소개
제14장 면책사항 및 문의
KSA 26.09.14Tuberculosis Therapeutics Market Summary
Overview:
- The Tuberculosis Therapeutics market is estimated at USD 4.15 billion in 2025 and is projected to reach USD 6.80 billion by 2034. Growth is anchored in the persistently high global TB burden, accelerating rollout of shorter all-oral drug-resistant TB regimens, and expanding access to next-generation anti-TB drugs across high-burden countries.
- The global Tuberculosis Therapeutics market is growing at a CAGR of 5.7% during the forecast period from 2026 to 2034.
- By drug type, the first-line anti-tuberculosis drugs segment dominated the Tuberculosis Therapeutics market with a 54% share in 2025.
- By disease type, the active TB segment dominated the Tuberculosis Therapeutics market with a 69% share in 2025.
- By formulation, the tablets segment dominated the Tuberculosis Therapeutics market with a 61% share in 2025.
- By patient type, the adult segment dominated the Tuberculosis Therapeutics market with a 72% share in 2025.
- By distribution channel, the hospital pharmacies segment dominated the Tuberculosis Therapeutics market with a 44% share in 2025.
- Asia-Pacific dominated the global Tuberculosis Therapeutics market revenue with a 49% share in 2025, representing the highest regional market share globally, reflecting the concentration of the global TB burden in the region.
Tuberculosis therapeutics comprise the anti-tubercular medicines used to prevent, treat, and manage active TB, latent TB infection, and multidrug- and extensively drug-resistant TB (MDR-TB and XDR-TB) caused by Mycobacterium tuberculosis. Standard treatment of drug-susceptible active TB relies on a backbone of first-line agents, isoniazid, rifampicin, pyrazinamide, and ethambutol, most often delivered as fixed-dose combination tablets to improve adherence and reduce pill burden under directly observed treatment programs. Drug-resistant TB requires second-line agents, including bedaquiline, pretomanid, linezolid, delamanid, and fluoroquinolones, increasingly deployed in shorter, all-oral regimens such as BPaL and BPaLM that have replaced older 18-20 month injectable-containing regimens. The market is organized by drug type across first-line, second-line/drug-resistant, and fixed-dose combination therapies; by disease type across active TB, latent TB, MDR-TB, and XDR-TB; by formulation across tablets, capsules, and injections; by patient type across adult, pediatric, and geriatric populations; and by distribution channel across hospital pharmacies, retail pharmacies, online pharmacies, and other channels such as national TB program clinics. Driven by the scale of the global TB burden, the rapid adoption of shorter drug-resistant TB regimens, expanding generic access through voluntary licensing, and sustained government and global-health-partner investment, tuberculosis therapeutics remain a cornerstone of infectious-disease public health infrastructure worldwide.
Tuberculosis Therapeutics Market Key Growth Drivers
- The persistently high global TB burden is sustaining demand, with the WHO Global Tuberculosis Report 2025 estimating that TB affected 10.7 million people and caused over 1.2 million deaths in 2024.
- Rapid national and global adoption of the shorter, all-oral BPaLM/BPaL regimens for MDR/RR-TB, including India's September 2024 approval of BPaLM under its National TB Elimination Program, is expanding demand for bedaquiline, pretomanid, and linezolid.
- Voluntary licensing arrangements that opened generic manufacturing of bedaquiline and pretomanid to producers in high-burden low- and middle-income countries are broadening access and expanding the addressable generics market.
- Government-led national TB elimination programs and global health-partner procurement, including Global Fund and Global Drug Facility supply agreements, continue to underpin large-volume public-sector demand for first-line and FDC therapies.
- Growing investment in pediatric-friendly, dispersible fixed-dose combinations and expanded latent TB preventive therapy, including the rifapentine-based 3HP regimen, is widening the treated population.
- An active late-stage pipeline of novel anti-TB candidates and next-generation regimens from TB Alliance and industry partners is expected to sustain innovation-led growth through the forecast period.
- Persistent and, in some regions, rising rates of multidrug-resistant and extensively drug-resistant TB are increasing reliance on costlier, specialized second-line therapies.
Key Companies in Tuberculosis Therapeutics Market
The competitive landscape is led by the following active manufacturers:
- Johnson & Johnson
- Sanofi
- Lupin Limited
- Macleods Pharmaceuticals
- Lupin Pharmaceuticals
- Otsuka Pharmaceutical
- Sandoz
- Teva Pharmaceutical Industries
- Viatris
- Pfizer
- Novartis
Factors Contributing to the Growth of the Tuberculosis Therapeutics Market
Market Drivers
High and Persistent Global TB Burden
The single most powerful driver of the tuberculosis therapeutics market is the sheer scale of the disease burden. The WHO Global Tuberculosis Report 2025 estimates that TB affected 10.7 million people and caused more than 1.2 million deaths in 2024, keeping it among the leading causes of death worldwide from a single infectious agent. Roughly 87% of cases are concentrated in 30 high-burden countries, led by India, Indonesia, the Philippines, China, Pakistan, Nigeria, the Democratic Republic of the Congo, and Bangladesh. Although the global TB incidence rate fell 12% and TB deaths fell 29% between 2015 and 2024, both reductions remain well short of the End TB Strategy's 2025 milestones, meaning the absolute number of patients requiring treatment stays large. This sustained caseload anchors durable, high-volume demand for first-line regimens, FDC tablets, and specialized drug-resistant therapies across the forecast period.
Rapid Adoption of Shorter, All-Oral Drug-Resistant TB Regimens
The shift from lengthy, injectable-containing MDR-TB regimens toward shorter, all-oral combinations is reshaping demand within the market. The WHO-recommended six-month BPaLM regimen, bedaquiline, pretomanid, linezolid, and moxifloxacin, replaces regimens that could run 18 to 20 months, improving completion rates and patient tolerability. India's Ministry of Health and Family Welfare approved BPaLM under its National TB Elimination Program in September 2024, extending the shorter regimen to tens of thousands of drug-resistant TB patients, and other high-burden countries are following a similar adoption path. Because BPaLM concentrates demand on a small set of second-line molecules, it is directly expanding the addressable market for bedaquiline, pretomanid, and linezolid manufacturers and their generic counterparts.
Market Restraints
Despite favorable demand fundamentals, the tuberculosis therapeutics market faces material constraints. Global TB funding remains critically short, with WHO reporting that funding sits at only about 25% of the 2027 target and warning that sustained donor funding cuts could result in up to 2 million additional TB deaths and 10 million additional cases between 2025 and 2035, directly threatening program-level drug procurement and treatment continuity. Diagnostic gaps compound this risk, as rapid molecular testing coverage reached only 54% in 2024, leaving a substantial share of cases undiagnosed, untreated, or treated empirically without confirmation of resistance status. Generic price erosion, while beneficial for access, compresses margins for first-line and increasingly second-line manufacturers as competition intensifies following voluntary licensing expansion. Treatment adherence remains challenging even under shortened regimens, given side-effect profiles associated with linezolid and other second-line agents, and stigma, poverty, and weak health infrastructure continue to limit access and completion rates in the highest-burden geographies. A comparatively thin late-stage pipeline of genuinely novel mechanisms, reliance on a small number of second-line molecules, and uneven diagnostic and treatment infrastructure across low-income regions further temper the pace of growth, even as the underlying drivers of disease burden, regimen innovation, and generic access remain firmly intact.
Tuberculosis Therapeutics Market Segment Analysis
The tuberculosis therapeutics market by drug type (first-line anti-tuberculosis drugs, second-line / drug-resistant tb drugs, fixed-dose combination (fdc) therapies), disease type (active tb, latent tb, mdr-tb, and xdr-tb), formulation (tablets, capsule, injections), patient type (adult, pediatric, geriatric), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).
By Drug Type
Dominant Subsegment: First-Line Anti-Tuberculosis Drugs.
The first-line anti-tuberculosis drugs segment accounted for 54% of the Tuberculosis Therapeutics market in 2025. First-line drugs, isoniazid, rifampicin, pyrazinamide, and ethambutol, remain the leading drug type because they form the standard six-month regimen recommended for the large majority of newly diagnosed, drug-susceptible active TB patients under national TB programs worldwide. Their inclusion on the WHO Essential Medicines List, broad off-patent generic availability, and central role in public-sector procurement through national TB elimination programs and pooled mechanisms such as the Global Drug Facility sustain very large, recurring volumes. Fixed-dose combination formulations of these agents further reinforce the segment by improving adherence and simplifying procurement and dispensing. While second-line and drug-resistant TB drugs are the fastest-growing drug type, propelled by BPaLM rollout, the sheer scale of drug-susceptible TB caseloads secures first-line therapies' leadership across the forecast period.
By Disease Type
Dominant Subsegment: Active TB.
The active TB segment accounted for 69% of the Tuberculosis Therapeutics market in 2025. Active TB is the leading disease type because it represents the overwhelming majority of diagnosed and treated cases globally, with the WHO Global Tuberculosis Report 2025 estimating that TB affected 10.7 million people in 2024, the large majority with active pulmonary or extrapulmonary disease requiring immediate multidrug therapy. National TB programs prioritize case-finding and treatment initiation for active disease under directly observed treatment protocols, driving consistent, high-volume consumption of first-line and, where resistance is confirmed, second-line therapies. MDR-TB and XDR-TB, while accounting for a smaller share of cases, are the fastest-growing disease types in value terms given their materially higher per-patient drug cost, and latent TB treatment is expanding as preventive therapy scales up. Nonetheless, the scale of the active TB caseload secures its clear leadership across the forecast period.
Tuberculosis Therapeutics Market Region Analysis
Dominant Region: Asia-Pacific
Asia-Pacific accounted for 49% of the global Tuberculosis Therapeutics market revenue in 2025, representing the highest regional market share globally. The region's dominance directly reflects the concentration of the global TB burden, with the WHO Global Tuberculosis Report 2025 attributing roughly 87% of cases to 30 high-burden countries, led by India at approximately 25% of the global caseload, followed by Indonesia, the Philippines, China, and Pakistan. Large-scale national TB elimination programs, including India's NTEP and China's TB control initiatives, drive substantial public-sector procurement of first-line FDCs and expanding drug-resistant TB regimens. The region also hosts a dense base of generics manufacturing, including Lupin, Macleods, and other Indian producers that supply both domestic programs and international markets through WHO prequalification and Global Drug Facility channels. Rising diagnostic capacity, expanding BPaLM rollout, and sustained government investment anchor the region's continued leadership across the forecast period.
Fastest Growing Region: Rest of World
Rest of World is the fastest-growing region in the Tuberculosis Therapeutics market. The region's elevated growth rate is driven by rising TB-HIV coinfection burden and expanding case-finding across Sub-Saharan Africa, growing Global Fund and international donor-supported procurement of both first-line and drug-resistant TB therapies, and the phased rollout of shorter BPaLM/BPaL regimens across African and Middle Eastern national TB programs. Nigeria and the Democratic Republic of the Congo, both among the WHO's highest-burden countries, are scaling diagnostic and treatment infrastructure, while regional manufacturing partnerships and technology transfer agreements are gradually expanding local production capacity. Continued donor engagement, expanding preventive therapy coverage, and infrastructure build-out position Rest of World as the principal source of incremental growth over the forecast period, even as funding volatility remains a key risk to sustaining this trajectory.
Regional Commentary
North America
North America is a comparatively small but stable market, reflecting low domestic TB incidence relative to global high-burden regions. Demand centers on treatment of imported and drug-resistant cases, robust public health surveillance, and reliable access to newer second-line agents including bedaquiline and pretomanid through well-funded national and state TB control programs.
Europe
Europe combines low overall TB incidence with a defined drug-resistant TB burden concentrated in parts of Eastern Europe and among migrant populations. Established EMA regulatory pathways, strong national TB surveillance systems, and coordinated procurement support consistent access to both first-line and newer all-oral drug-resistant regimens across Germany, the United Kingdom, France, Italy, and Spain.
Asia-Pacific
Asia-Pacific is the largest regional market, propelled by the concentration of global TB burden in India, China, Indonesia, the Philippines, and Pakistan, extensive national TB elimination programs, and a deep base of generic anti-TB drug manufacturing that supplies both domestic and international markets.
Rest of World
The Rest of World region, spanning Sub-Saharan Africa, the Middle East, and Latin America, is an emerging growth frontier shaped by high TB-HIV coinfection rates, expanding Global Fund-supported procurement, and gradual local manufacturing capacity build-out, tempered by continued dependence on international donor financing.
Tuberculosis Therapeutics Market Competitive Landscape
The Tuberculosis Therapeutics market is classified as Moderately Fragmented. A group of originator companies with proprietary second-line agents and global regulatory reach, including Johnson & Johnson, Otsuka Pharmaceutical, and Sanofi, anchors the branded segment, while large generics and FDC manufacturers, including Lupin Limited, Lupin Pharmaceuticals, Macleods Pharmaceuticals, Sandoz, Teva Pharmaceutical Industries, Viatris, Pfizer, and Novartis, compete on scale, WHO prequalification, and public-sector procurement contracts, increasing competition as voluntary licensing broadens access to second-line molecules.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Moderately fragmented, with originator companies anchoring proprietary second-line agents and a broad base of generics manufacturers competing on first-line and FDC supply.
- Leading players: Johnson & Johnson, Sanofi, and Otsuka Pharmaceutical anchor the branded, innovator segment through proprietary bedaquiline, rifapentine, and delamanid franchises.
- Geographic reach: Leaders operate global supply networks essential to national TB programs; Indian manufacturers including Lupin and Macleods supply both domestic programs and international markets through WHO prequalification.
- Product portfolio strength: Top players offer first-line FDCs, second-line drug-resistant TB agents, and pediatric-friendly dispersible formulations across the treatment continuum.
- Access and licensing: Voluntary licensing and non-exclusive supply agreements coordinated through the Stop TB Partnership's Global Drug Facility have expanded generic manufacturing access to bedaquiline and pretomanid, a decisive factor in market structure.
- Strategic partnerships: Collaborations between originator companies, TB Alliance, and generics manufacturers, such as pediatric formulation development with Macleods Pharmaceuticals, extend reach into underserved patient populations.
- Procurement relationships: Strong positioning with the Global Fund, Global Drug Facility, and national TB elimination programs is a key competitive advantage given the public-sector-driven nature of TB drug demand.
- Manufacturing capabilities: WHO-prequalified, GMP-compliant manufacturing capacity and fixed-dose combination formulation expertise are key competitive moats.
- Innovation focus: Shorter all-oral regimen development, pediatric and latent TB formulations, and next-generation drug-resistant TB candidates such as TBAJ-876 define the innovation frontier.
Tuberculosis Therapeutics Market Recent Developmental Activities
In November 2025, the World Health Organization released the Global Tuberculosis Report 2025, confirming that funding sits at only about 25% of the 2027 target and warning that continued donor funding cuts could result in up to 2 million additional TB deaths and 10 million additional cases between 2025 and 2035. Strategic significance: Highlights the funding risk that could disrupt anti-TB drug procurement and treatment continuity across high-burden countries.
In September 2024, India's Ministry of Health and Family Welfare approved the introduction of the BPaLM regimen, a four-drug combination of bedaquiline, pretomanid, linezolid, and moxifloxacin, under the National TB Elimination Program as the new standard shorter treatment for drug-resistant TB. Strategic significance: Expands demand for bedaquiline, pretomanid, and linezolid across one of the world's largest drug-resistant TB patient populations.
Tuberculosis Therapeutics Market Segmentation
Tuberculosis Therapeutics Market by Drug Type
- First-Line Anti-Tuberculosis Drugs
- Second-Line / Drug-Resistant TB Drugs
- Fixed-Dose Combination (FDC) Therapies
Tuberculosis Therapeutics Market by Disease Type
- Active TB
- Latent TB
- MDR-TB
- XDR-TB
Tuberculosis Therapeutics Market by Formulation
- Tablets
- Capsule
- Injections
Tuberculosis Therapeutics Market by Patient Type
- Adult
- Pediatric
- Geriatric
Tuberculosis Therapeutics Market by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Tuberculosis Therapeutics Market by Geography
- North America Tuberculosis Therapeutics Market
- United States Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Canada Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Mexico Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Europe Tuberculosis Therapeutics Market
- Germany Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- United Kingdom Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- France Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Italy Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Spain Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Rest of Europe Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Asia-Pacific Tuberculosis Therapeutics Market
- China Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Japan Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- India Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Australia Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- South Korea Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Rest of the World (RoW) Tuberculosis Therapeutics Market
- Middle East Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- Africa Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- South America Tuberculosis Therapeutics Market Size in USD million (2023-2034)
Key Takeaways from the Tuberculosis Therapeutics Market Report Study
- Market size analysis for the current Tuberculosis Therapeutics market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global Tuberculosis Therapeutics market.
- Various opportunities available for competitors in the Tuberculosis Therapeutics market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current Tuberculosis Therapeutics market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for Tuberculosis Therapeutics market growth in the future?
Target audience who can benefit from this Tuberculosis Therapeutics market report study
- Tuberculosis Therapeutics product providers
- Research organizations and consulting companies
- Tuberculosis Therapeutics -related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in Tuberculosis Therapeutics
- Various end-users who want to know more about the Tuberculosis Therapeutics market and the latest technological developments in the Tuberculosis Therapeutics market.
Frequently Asked Questions:
Q1. What is the growth rate of the Tuberculosis Therapeutics market?
The Tuberculosis Therapeutics market is projected to expand at a CAGR of 5.7% during the forecast period from 2026 to 2034.
Q2. What is the market size of the Tuberculosis Therapeutics market?
The Tuberculosis Therapeutics market is estimated at USD 4.15 billion in 2025 and is projected to reach USD 6.80 billion by 2034.
Q3. Which region dominates the Tuberculosis Therapeutics market?
Asia-Pacific dominated the tuberculosis therapeutics market with a 49% share of global revenue in 2025, supported by the concentration of the global TB burden in India, China, Indonesia, the Philippines, and Pakistan, extensive national TB elimination programs, and a deep base of generic manufacturing. Rest of the World is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Tuberculosis Therapeutics market?
The principal drivers are the high and persistent global TB burden, with WHO estimating 10.7 million people affected and over 1.2 million deaths in 2024; rapid adoption of shorter, all-oral BPaLM/BPaL regimens for drug-resistant TB; expanding generic access through voluntary licensing; sustained government and global health-partner investment; and growth in pediatric and latent TB treatment.
Q5. Who are the major players in the Tuberculosis Therapeutics market?
The major players include Johnson & Johnson, Sanofi, Lupin Limited, Macleods Pharmaceuticals, Lupin Pharmaceuticals, Otsuka Pharmaceutical, Sandoz, Teva Pharmaceutical Industries, Viatris, Pfizer, and Novartis, among other active manufacturers profiled in the Competitive Landscape section.
Table of Contents
1. Tuberculosis Therapeutics Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
2. Tuberculosis Therapeutics Market Executive Summary
- 2.1 Market at a Glance
3. Tuberculosis Therapeutics Market Key Factors Analysis
- 3.1 Tuberculosis Therapeutics Market Drivers
- 3.1.1 High and Persistent Global TB Burden
- 3.1.2 Adoption of Shorter, All-Oral Drug-Resistant TB Regimens
- 3.1.3 Expanding Generic Access Through Voluntary Licensing
- 3.1.4 Government and Global Health-Partner Investment
- 3.2 Tuberculosis Therapeutics Market Restraints and Challenges
- 3.2.1 Funding Gaps and Diagnostic Coverage Shortfalls
- 3.2.2 Adherence, Access, and Infrastructure Barriers
- 3.2.3 Generic Price Erosion and Pipeline Concentration
- 3.3 Tuberculosis Therapeutics Market Opportunities
- 3.3.1 Pediatric and Latent TB Formulation Expansion
- 3.3.2 Next-Generation Regimen and Universal Therapy Development
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
6. Tuberculosis Therapeutics Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
7. Tuberculosis Therapeutics Market Assessment
- 7.1 By Drug Type
- 7.1.1 First-Line Anti-Tuberculosis Drugs
- 7.1.2 Second-Line / Drug-Resistant TB Drugs
- 7.1.3 Fixed-Dose Combination (FDC) Therapies
- 7.2 By Disease Type
- 7.2.1 Active TB
- 7.2.2 Latent TB
- 7.2.3 MDR-TB
- 7.2.4 XDR-TB
- 7.3 By Formulation
- 7.3.1 Tablets
- 7.3.2 Capsule
- 7.3.3 Injections
- 7.4 By Patient Type
- 7.4.1 Adult
- 7.4.2 Pediatric
- 7.4.3 Geriatric
- 7.5 By Distribution Channel
- 7.5.1 Hospital Pharmacies
- 7.5.2 Retail Pharmacies
- 7.5.3 Online Pharmacies
- 7.5.4 Others
- 7.6 By Geography
- 7.6.1 North America
- 7.6.1.1 United States Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.1.2 Canada Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.1.3 Mexico Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.2 Europe
- 7.6.2.1 Germany Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.2 United Kingdom Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.3 France Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.4 Italy Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.5 Spain Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.2.6 Rest of Europe Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.3 Asia-Pacific
- 7.6.3.1 China Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.2 Japan Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.3 India Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.4 Australia Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.5 South Korea Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.3.6 Rest of Asia-Pacific Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.4 Rest of World
- 7.6.4.1 Middle East Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.4.2 Africa Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.4.3 South America Tuberculosis Therapeutics Market Size in USD million (2023-2034)
- 7.6.1 North America
8. Tuberculosis Therapeutics Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
9. Tuberculosis Therapeutics Market Startup Funding and Investment Trends
10. Tuberculosis Therapeutics Market Company and Product Profiles
- 10.1 Johnson & Johnson
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 Sanofi
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 Lupin Limited
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 Macleods Pharmaceuticals
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 Lupin Pharmaceuticals
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 Otsuka Pharmaceutical
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 Sandoz
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 Teva Pharmaceutical Industries
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 Viatris
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
- 10.10 Pfizer
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
